ClinicalTrials.gg
CompletedNCT03110276Updated Apr 13, 2017

Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

A Phase 1 interventional study of EYP001a and Placebo in Healthy, sponsored by Enyo Pharma. Completed. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-13.

Sponsored by Enyo Pharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2016, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of hepatitis B.

This Phase 1 study is designed primarily to evaluate the single ascending dose (SAD) followed by a multiple ascending dose (MAD) safety, tolerability, and pharmacokinetics of EYP001a in healthy male subjects.

Read the detailed description

This is a two-part, randomized, double-blind, placebo-controlled study. Healthy male subjects will be randomly assigned to receive EYP001a or placebo.

In the SAD part, up to 6 cohorts will receive EYP001a single doses of 30 mg, 60 mg, 120 mg, 250 mg, 500 mg, and 800 mg. In the MAD part, 4 cohorts will receive EYP001a doses of 60, 120, 250 and 500 mg, once daily for 14 days over 15-day period. Each cohort will include 6 active \& 2 placebo subjects. Dose escalation will depend on evaluation of safety parameters.

Participation will include up to 21-day screening period followed by dosing period (1 to 15 days). A follow-up evaluation will occur at 6 ± 2 days post final dose.

Safety and tolerability will be assessed by monitoring adverse events, laboratory values, ECG parameters, and vital signs.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Enyo Pharma is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-

Subjects must satisfy all of the following inclusion criteria during screening to be enrolled in the study:

  1. Subject has given voluntary written before performance of any study related procedure
  2. Subject must be 18 to 50 years of age, inclusive at screening
  3. Subject must have clinical chemistries, hematology, and urinalysis tests within normal, allowable limits (if out of range must be considered to be exclusionary) and performed within 21 days of receiving first dose of study drug
  4. Subject must have a of between 18 and 30 kg/m2 at screening
  5. Subject must have weight > 60 kg at screening
  6. Subject must have normal vital signs after 5 minutes resting in supine position at screening:

    • 95 mm Hg \< systolic blood pressure \< 140 mm Hg
    • 45 mm Hg \< diastolic blood pressure \< 90 mm Hg
    • 40 bpm \< pulse rate \< 90 bpm
  7. Subject must have a normal 12-lead automatic (incomplete right bundle branch block can be accepted): 120 ms \< PR \< 210 ms, QRS \< 120 ms, interval (QTc) (Fridericia) ≤ 450 msec at screening.
  8. Agree to abstain from all medication, including non-prescription and prescription medication (including vitamins and natural or herbal remedies, e.g. St. John's Wort) for 21 days before the first study day until discharge from the study (end of post study medical).
  9. Subject agrees to use condom from dosing through 90 days after the dose of study drug. Female partners of male subjects enrolled into this study are also recommended to use an acceptable method of (i.e., a hormonal contraceptive, intra-uterine device,diaphragm, condom, or abstinence).

Exclusion criteria

Exclusion Criteria:

-

Subjects meeting any of the following exclusion criteria are not to be enrolled in the study:

  1. A history of gastrointestinal, especially peptic ulcerations, gastrointestinal bleeding, ulcerative colitis, cholecystectomy, Crohn's disease or Irritable Bowel Syndrome, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, especially those with a past history of depression, suicidal ideation or suicidal attempts, or cardiovascular disease or any other condition which, in the opinion of the principle investigator, would jeopardize the safety of the subject or impact the validity of the study results
  2. Acute diarrhea or constipation in the 7 days before the predicted first study day. If screen occurs >7 days before first study day, this criterion will be determined on first study day. Diarrhea will be defined as the passage of liquid feces and/or a stool frequency of > 3 times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
  3. Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration
  4. Regular alcohol consumption >21 units per week (1 Unit = 1⁄2 pint beer, 25 mL shot of 40% spirit or a 125 mL glass of wine)
  5. Subject has a borderline or long Fridericia interval as defined by screening readings of > 450
  6. Subject has participated in a drug study within 60 days prior to the first drug administration in the current study
  7. Subject has used any over-the-counter (OTC) medication, including vitamins, within 21 days prior to the study
  8. Subject has used any prescription medication within 21 days prior to the study
  9. Subject has been treated with any known P450 3A4 or 2D6 enzyme altering drugs within 30 days prior to the study
  10. Subject smoking more than 5 cigarettes per day
  11. Subject has sought advice from or been referred to a general practioner or counselor for abuse or misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, e.g. solvents
  12. Subject has a positive blood screen for , surface antigen (HBsAg), and Antibody and/or a positive urine screen for alcohol or drugs of abuse
  13. Any current or previous use of drugs such as opiates, cocaine, ecstasy, or intravenous amphetamines

    • Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs-of-abuse test and have been abstinent from cannabis use for at least 3 months
  14. Subject has an uncontrolled inter-current illness (i.e., active infection)
  15. Subject has had major surgery within four weeks of study entry, or 12 months prior to study for gastrointestinal surgery.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    EYP001a

    Drug: EYP001a

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).

    Also known as: EYP001

  • DrugPlacebo

    Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.

06

What researchers measure

Primary outcomes

  1. Number of subjects reported with adverse events, serious adverse events

    Time frame: 7 days (SAD) or 21 days (MAD)

Secondary outcomes

  1. Maximum plasma concentration (Cmax) of EYP001

    ng/mL

    Time frame: Days 1 & 2 (SAD and MAD). Days 14 & 15 (MAD)

  2. Time to reach maximum concentration after drug administration (Tmax) of EYP001

    hours

    Time frame: Days 1 & 2 (SAD and MAD). Days 14 & 15 (MAD)

  3. Area under the plasma concentration-time profile (AUCtau) of EYP001

    ng.h/mL

    Time frame: Days 1 & 2 (SAD and MAD). Days 14 & 15 (MAD)

  4. C4 (7α-hydroxy-4-cholesten-3-one)

    ng/mL

    Time frame: Days 1 & 2 (SAD). Days 1, 7 & 15 (MAD)

  5. fibroblast growth factor 19 Fibroblast growth factor 19 (FGF19)

    pg/mL

    Time frame: Days 1 & 2 (SAD). Days 1, 7 & 15 (MAD)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2016 to primary completion in Mar 2017, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2017
First posted
Apr 12, 2017
StartActual
Aug 2016
Primary completionActual
Mar 2017
CompletionActual
Mar 2017
Last update
Apr 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03110276
Lead sponsor
Enyo Pharma
Collaborators
PRA Health Sciences
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Aug 2016
Primary completion
Mar 2017
Completion
Mar 2017
Last update
Apr 13, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EYP001A

Start the discussion